The ATXN3 gene gives your cells instructions for a protein that helps control and recycle other proteins. This gene plays an important role in keeping nerve cells healthy. When the ATXN3 gene carries an expanded repeat variant, the protein can fold the wrong way and build up inside cells, which can damage the brain and nerves. This causes spinocerebellar ataxia type 3, also called Machado-Joseph disease, which often affects balance, walking, speech, and eye movements.
What is a gene?
A gene is a stretch of DNA that carries information cells use to make molecules or regulate processes in the body. Some genes provide the instructions for building proteins, which do much of the work inside cells. Other genes mostly control when certain activities take place, where they happen, and how strongly they are carried out. Together, genes affect how the body develops and works, and they can also influence how you respond to food, stress, or medications. To explore this topic in greater detail, you can find more in the LearnHub.
Overview
ATXN3Gene function
What if the gene works
The ATXN3 gene helps cells manage and recycle proteins, especially proteins tagged for breakdown. Its protein also supports normal cell stress responses and helps keep nerve cells working steadily.
Risk
What if the gene does not work
Certain expanded repeats in the ATXN3 gene can cause Machado-Joseph disease, leading to progressive problems with balance, walking, coordination, speech, swallowing, and eye movements. Larger expansions often bring earlier symptoms and can make features more pronounced.
Treatment
What does that mean for your treatment
No ATXN3-specific treatment or drug choice is currently established in clinical guidelines, so care remains based on symptoms rather than the variant itself. The ATXN3 gene is being studied as a drug target, including therapies that aim to lower harmful ataxin-3 in spinocerebellar ataxia type 3.
Conditions associated with ATXN3
Gene function
What if the gene works
Inside your cells, the ATXN3 gene helps manage how proteins are labeled and handled. Its protein acts like an editor for ubiquitin tags (small labels that guide protein recycling and disposal). This supports smooth protein quality control, a basic part of what the ATXN3 gene does in your cells every day.
Ataxin-3 trims ubiquitin tags (small labels that tell a cell how to handle a protein). This helps proteins be sorted more precisely for reuse, movement, or breakdown.
By editing these tags, the ATXN3 gene supports the proteasome (the cell’s protein disposal system). This helps routine cleanup stay organized as proteins become old, extra, or worn out.
Careful protein handling helps cells keep their inner environment steady. This is especially important in long-lived cells that depend on reliable day-to-day maintenance.
What is a variant?
A genetic variant is a minor change in the DNA sequence within a gene. These changes are common and help create normal human diversity, including differences in appearance, metabolism, and how the body reacts to environmental influences. Many variants do not cause any noticeable effects and are simply part of natural genetic variation. In some cases, though, a variant can more clearly affect how a gene works and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Most established harmful variants in the ATXN3 gene are CAG repeat expansions that make the ataxin-3 protein unusually long. This longer protein can fold poorly, stick to other proteins, and form clumps inside nerve cells, showing how variants in the ATXN3 gene change protein function in spinocerebellar ataxia type 3. Shorter expansions may cause a milder functional change, while larger expansions often disrupt cells more and are linked to earlier or more pronounced symptoms.
How variants are linked to conditions
An expanded CAG repeat in the ATXN3 gene causes spinocerebellar ataxia type 3, an inherited neurologic condition also called Machado-Joseph disease. This means ATXN3 gene variants linked to spinocerebellar ataxia type 3 can lead to gradually worsening balance and coordination problems, often with speech, swallowing, vision, or muscle stiffness changes. Different repeat lengths are associated with differences in the age symptoms begin and how the condition shows up within families.
A variant is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are common throughout the general population. Most do not have a direct effect on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition indicates a possible link rather than a definite diagnosis, especially when more than one gene and environmental factors are involved. In some cases, though, a single well-characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
If you carry a disease-causing change in the ATXN3 gene, the chance of developing spinocerebellar ataxia type 3 is largely determined by that variant, and longer repeat expansions often lead to symptoms starting earlier. There is not enough evidence to say lifestyle changes lower this risk, but regular follow-up can help with early support and reducing complications.
Inheritance of ATXN3 variants
Variants in the ATXN3 gene linked to spinocerebellar ataxia type 3 are inherited in an autosomal dominant pattern. This means a parent carrying the variant can pass it to a child with a 50% chance in each pregnancy, whether the child is a son or a daughter. In practical terms, how ATXN3 gene variants are inherited usually means the condition can be seen across several generations in a family.
What does my ATXN3 result mean for my family?
For families with a disease-causing change in the ATXN3 gene, close relatives such as parents, brothers, sisters, and children may also carry the same change and may want to learn their own status. This gene is usually passed down in a dominant pattern, so each child of an affected parent has a 1 in 2, or 50%, chance of inheriting it. In some families, symptoms can appear at a younger age in the next generation.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the ATXN3 gene, doctors use genetic testing for spinocerebellar ataxia type 3 on a blood or saliva sample. The lab examines your DNA and usually counts CAG repeats, a short sequence repeated in a row. This shows whether an expanded repeat in the ATXN3 gene is present.
When should I consider getting a genetic test?
Consider ATXN3 testing if you have slowly worsening balance, walking, coordination, speech, or swallowing problems, especially if similar symptoms run in your family. It can also be considered when several relatives across generations have been told they have Machado-Joseph disease or spinocerebellar ataxia. A positive result can help confirm the cause of symptoms.
A genetic result is only one part of your health story
A genetic result can provide useful insight, but how much it reveals varies depending on the condition and the specific type of variant. Over time, factors such as age, environment, lifestyle, and medical history also influence how the body works. For some conditions, especially those shaped by many genes, genetic information offers context rather than certainty and is most useful when considered alongside other parts of care. In other situations, a genetic result can give a clear answer. In areas like medication response, genetic results can also help put individual experiences in context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. This happens because inherited differences can change how the body breaks down a drug, moves it through the bloodstream, or responds to it at its target. As a result, the same medication may work better for some people, have less effect in others, or make some people more sensitive to side effects. This kind of variation is common and is one reason treatment response can differ from person to person.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences can affect the way a person responds to medications. It studies links between genes and drugs to help explain why treatment effects can vary from one person to another. For many medicines, genes influence how strongly a drug works or how the body handles it. This information can support more informed, more individualized treatment decisions. You can read more about this topic in the LearnHub.
Drugs influenced by the ATXN3 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choice or dose. If you have concerns about side effects, new symptoms, or how medicines affect your daily function, discuss them with your doctor.
History
The ATXN3 gene entered medical history through families with an inherited movement condition now called spinocerebellar ataxia type 3, also widely known as Machado-Joseph disease. Doctors first recognized the pattern in families of Portuguese Azorean ancestry, where several relatives across generations developed balance problems, clumsiness, and changes in speech or eye movements. In the 1990s, researchers mapped the condition to chromosome 14 and then identified the ATXN3 gene as the cause in affected families. From these first observations, research expanded steadily. The discovery helped show that several inherited ataxias are caused by expanded repeated DNA segments, which became a major advance in neurogenetics. Today, the history of the ATXN3 gene remains closely tied to improving diagnosis and family counseling for spinocerebellar ataxia.